# Anonymous Data Donation Program

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Chief Science Officer & Privacy Officer
**Purpose**: Establish comprehensive patient data donation program enabling AATD patients to contribute genetic, clinical, and lifestyle data for research while maintaining privacy, accelerating scientific discovery, and creating world's largest AATD research database

---

## ðŸ“‹ Table of Contents

1. [The Data Gap in AATD Research](#the-data-gap)
2. [What Patients Can Donate](#what-patients-can-donate)
3. [Privacy & Security Framework](#privacy-security-framework)
4. [Informed Consent Process](#informed-consent-process)
5. [Data Collection Methods](#data-collection-methods)
6. [Research Access Governance](#research-access-governance)
7. [Patient Incentives](#patient-incentives)
8. [Technical Infrastructure](#technical-infrastructure)
9. [Legal & Ethical Considerations](#legal-ethical-considerations)
10. [Implementation Roadmap](#implementation-roadmap)

---

## The Data Gap in AATD Research

### Why AATD Research is Data-Starved

**The Problem**:

- **Small patient population** (100,000 US patientsâ€”rare disease, limited research subjects)
- **Fragmented care** (patients see different doctors, different hospitalsâ€”data siloed, no unified view)
- **Research barriers** (recruiting patients = slow/expensive, clinical trials take 3-5 years to enroll 100 patients)
- **Lack of natural history data** (researchers don't know typical disease progressionâ€”makes trials harder to design, interpret)

**Current State**:

- AlphaNet registry: ~3,000 patients (3% of diagnosed US patients)
- Alpha-1 Foundation registry: ~1,000 patients (1%)
- Academic registries combined: ~2,000 patients (fragmented, not shared)
- **Total**: ~5,000 patients with registry data (5% of diagnosed, 0.05% of all AATD patientsâ€”researchers starved for data)

---

### Foundation's Opportunity: Build World's Largest AATD Database

**Vision**: 10,000-patient registry by Year 10 (10% of all US AATD patientsâ€”10x larger than any existing registry)

**How Data Donation Enables Research**:

**1. Natural History Studies** (Understand Disease Progression)

- Current gap: "How fast does lung function decline in Pi*ZZ vs. Pi*SZ?" (unclearâ€”limited data)
- With data: Track 5,000 Pi\*ZZ patients over 10 years (FEV1 measurements, exacerbations, hospitalizationsâ€”definitive answer)
- **Impact**: Researchers design better trials (know expected decline rateâ€”calculate sample sizes, trial durations accurately)

**2. Treatment Effectiveness** (Real-World Evidence)

- Current gap: "Does augmentation therapy work long-term?" (clinical trials = 2-3 years, real world = 20+ years, data gap)
- With data: Compare 2,000 patients on augmentation vs. 2,000 not on therapy (matched for age, severity, smokingâ€”observational study)
- **Impact**: Prove therapy works (or doesn't)â€”influence insurance coverage, FDA, patient decisions

**3. Genotype-Phenotype Correlations** (Precision Medicine)

- Current gap: "Why do some Pi\*ZZ patients have severe lung disease at 40, others mild at 70?" (genetic modifiers unknown)
- With data: Whole genome sequence 1,000 patients (identify protective genes, risk genesâ€”personalize treatment)
- **Impact**: Predict who needs aggressive therapy, who can wait (precision medicineâ€”right treatment, right patient, right time)

**4. Clinical Trial Acceleration** (Faster Drug Development)

- Current gap: Recruiting 100 patients for gene therapy trial = 3 years (expensive, delays cure)
- With data: Foundation registry = trial-ready patients (pre-screened, pre-consented, contact in databaseâ€”recruit 100 in 3 months, not 3 years)
- **Impact**: Gene therapy approved 2 years faster (2032 vs. 2034â€”thousands of patients benefit sooner)

---

## What Patients Can Donate

### Tier 1: Basic Data (Every Participant)

**Demographics** (No PHIâ€”De-identified):

- Age (year of birth, not exact birthdateâ€”balance utility + privacy)
- Sex (male/female/otherâ€”biological sex for research, not gender identity here)
- Race/ethnicity (importantâ€”AATD prevalence varies, Northern European highest)
- Geographic region (state or ZIP first 3 digitsâ€”track environmental exposures, access to care, not exact address)

**Genetic Data** (Foundation's Most Valuable Asset):

- SERPINA1 genotype (Pi*ZZ, Pi*SZ, Pi\*MZ, rare variantsâ€”definitive diagnosis)
- Full sequence if available (whole SERPINA1 geneâ€”identify novel mutations, improve diagnostics)
- Whole genome optional (patients can opt inâ€”23andMe raw data, clinical sequencing, advanced research)

**Medical History**:

- AATD symptoms (lung disease, liver disease, panniculitis, age of onsetâ€”natural history)
- Comorbidities (COPD, asthma, bronchiectasis, cirrhosisâ€”disease overlap, treatment implications)
- Medications (augmentation therapy brand/frequency, inhalers, liver medsâ€”treatment patterns)
- Smoking history (never/former/current, pack-yearsâ€”#1 risk factor, essential variable)

**Family History**:

- First-degree relatives with AATD (yes/no, how manyâ€”genetic counseling, cascade screening data)
- Family members diagnosed after index patient (measure cascade screening successâ€”Foundation's impact)

---

### Tier 2: Clinical Data (Engaged Participants, Annual Updates)

**Lung Function Tests** (Gold Standard Outcomes):

- FEV1 (forced expiratory volumeâ€”primary COPD outcome, track annually)
- FVC (forced vital capacity)
- DLCO (diffusion capacityâ€”gas exchange, sensitive measure)
- **Why valuable**: Researchers track disease progression (FEV1 decline rate = primary endpoint in clinical trialsâ€”natural history data = trial design)

**Imaging**:

- Chest CT reports (emphysema severity, location [upper lobe = AATD classic])
- Liver ultrasound/MRI (fibrosis stagingâ€”liver outcomes underresearched, Foundation fills gap)
- **Why valuable**: Imaging = objective measure (correlate with symptoms, genetics, predict outcomes)

**Lab Results**:

- AAT level (mg/dLâ€”track over time, augmentation therapy target trough levels)
- Liver function tests (ALT, AST, bilirubinâ€”monitor liver disease progression)
- **Why valuable**: Biomarkers = early disease detection (ALT rising before cirrhosis symptomsâ€”intervene earlier)

**Healthcare Utilization**:

- Hospitalizations (# per year, reasonsâ€”exacerbations, liver complications, disease burden)
- ER visits (frequencyâ€”quality of life, healthcare costs)
- Augmentation therapy adherence (% of doses receivedâ€”non-adherence = confounder in effectiveness studies)

**Why valuable**: Real-world data (clinical trials = controlled, real world = messyâ€”Foundation captures both, completes picture)

---

### Tier 3: Advanced Data (Research Super-Participants, Subset)

**Biospecimens** (Physical Samples):

- Blood (DNA, RNA, plasma, serumâ€”stored in biobank, researchers request)
- Sputum (respiratory cells, bacteriaâ€”lung microbiome studies, infection research)
- Liver biopsy tissue (if patient has biopsy for clinical careâ€”leftover tissue donated, not extra biopsy just for research)
- **Why valuable**: Enable omics research (genomics, transcriptomics, proteomics, metabolomicsâ€”next-gen science requires physical samples)

**Wearable Data** (Continuous Monitoring):

- FitBit, Apple Watch (steps, heart rate, sleepâ€”activity level, patient-reported vs. objective)
- Pulse oximetry (O2 saturationâ€”track oxygen use, desaturation during exertion, sleep apnea)
- **Why valuable**: Objective measures (patients forget exacerbations, wearables don'tâ€”capture true disease burden)

**Patient-Reported Outcomes (PROs)**:

- Quality of life (SF-36, SGRQâ€”validated surveys, quarterly)
- Symptom diaries (dyspnea, fatigue, exacerbationsâ€”daily app, track patterns)
- Mental health (PHQ-9 depression screen, GAD-7 anxietyâ€”AATD impacts mental health, underaddressed)
- **Why valuable**: Patient perspective (FEV1 may be stable, but patient feels worseâ€”PROs capture what matters to patients)

**Social Determinants**:

- Employment status (working, disabled, retiredâ€”disease impact on livelihood)
- Insurance type (private, Medicare, Medicaid, uninsuredâ€”access disparities)
- Income bracket (optionalâ€”sensitive but important, socioeconomic factors affect outcomes)
- **Why valuable**: Health equity research (do low-income patients have worse outcomes? why?â€”identify intervention opportunities)

---

### Tier 4: Long-Term Outcomes (Follow-Up Data, Years-Decades)

**Disease Progression**:

- FEV1 decline rate (mL/yearâ€”varies widely, 30-80 mL/year in AATD, Foundation tracks individual trajectories)
- Exacerbation frequency (# per yearâ€”increasing exacerbations = worsening disease, hospitalization risk)
- Oxygen initiation (date started O2â€”milestone in disease, quality of life impact)

**Major Events**:

- Lung transplant (date, center, outcomesâ€”survival, rejection, Foundation tracks AATD transplant outcomes)
- Liver transplant (sameâ€”AATD major transplant indication, especially pediatric)
- Death (date, causeâ€”ultimate outcome, Foundation mortality registry informs prognosis)

**Why valuable**: Longitudinal data (10-20 year follow-up = rare, preciousâ€”researchers can't wait 20 years for new trial, Foundation's data already collected)

---

## Privacy & Security Framework

### HIPAA Compliance & Beyond

**Foundation's Commitment**: Exceed HIPAA requirements (not just legal complianceâ€”ethical obligation, patient trust essential)

**Key Principles**:

1. **Voluntary participation** (patients opt inâ€”never required, can withdraw anytime, no penalty)
2. **Informed consent** (patients understand what data collected, how used, risks/benefitsâ€”transparent)
3. **De-identification** (remove 18 HIPAA identifiersâ€”name, address, phone, email, dates [except year], medical record numbers, photos [unless consented])
4. **Secure storage** (encrypted databases, access controls, audit logsâ€”track every data access, who, when, why)
5. **Limited access** (researchers request specific datasetsâ€”approve case-by-case, not open access to all data)

---

### De-Identification Process

**Step 1: Remove Direct Identifiers**

- Name â†’ Patient ID (P000001, P000002â€”unique identifier, not linked to name in researcher-accessible database)
- Address â†’ State or 3-digit ZIP (preserve geographic data for research, not exact location)
- Phone, email â†’ Removed (Foundation keeps separately for patient contactâ€”researchers never see)
- Dates â†’ Year only (birthdate â†’ year of birth, diagnosis date â†’ year of diagnosis, treatment start â†’ year started)

**Step 2: Generalize Quasi-Identifiers**

- Age â†’ Age range (38 â†’ 35-40â€”if exact age + rare disease + small town, re-identification possible)
- Rare diagnoses â†’ Categorized (patient has panniculitis + Pi\*null mutation [rare combo] â†’ category "rare variant + skin manifestation," less specific)

**Step 3: Expert Determination**

- Privacy officer reviews (statistician calculates re-identification riskâ€”"This dataset has <0.01% re-identification risk, acceptable")
- If risk too high â†’ further de-identification (e.g., combine age ranges, suppress rare genotypes)

**Result**: Data useful for research, but "anonymous" per HIPAA Safe Harbor or Expert Determination (gold standard)

---

### Re-Identification Safeguards

**Attacks to Prevent**:

1. **Direct matching** (researcher has patient's name, tries to find in datasetâ€”prevented by removing names, random IDs)
2. **Cross-database linking** (researcher combines Foundation data + public data [voter records, etc.]â€”links based on ZIP + age + sexâ€”prevented by generalizing quasi-identifiers)
3. **Insider threats** (Foundation employee steals dataâ€”prevented by access controls, audit logs, encryption)

**Technical Safeguards**:

- **Encryption at rest** (data on servers encryptedâ€”AES-256, if laptop stolen, data useless without key)
- **Encryption in transit** (data moving over internet encryptedâ€”HTTPS, VPN, prevent eavesdropping)
- **Role-based access** (researchers access only approved datasetsâ€”can't browse full database, query limits)
- **Audit logs** (every data access loggedâ€”who viewed Patient P000042 data? when? what fields?â€”detect/deter misuse)
- **Two-factor authentication** (researcher login = password + phone codeâ€”prevent unauthorized access)

**Organizational Safeguards**:

- **Data Use Agreements** (researchers sign contractâ€”"I won't try to re-identify patients, I won't share data with others, I'll delete data when done")
- **IRB oversight** (researchers submit protocol to Institutional Review Boardâ€”third-party review, ensure ethical research)
- **Foundation Scientific Advisory Board reviews** (every data requestâ€”"Is this scientifically sound? Ethical? Worth privacy risk?"â€”approve/deny)

---

## Informed Consent Process

### What Patients Consent To (Clear, Understandable Language)

**Consent Form Key Elements** (12-page document, 8th-grade reading level):

**Section 1: Purpose** (Why we're doing this)

- "The Mark Egly Foundation is building a research database to help scientists understand Alpha-1 and develop better treatments. Your data will be used for research studies approved by our Scientific Advisory Board."

**Section 2: What We'll Collect** (Be specific)

- "We'll collect your medical records, test results, genetic information, and ask you to complete surveys. You can choose how much data to shareâ€”basic, detailed, or everything including biospecimens."

**Section 3: How We'll Use Your Data** (Transparency)

- "Researchers will use your data to study disease progression, test effectiveness, genetic risk factors, and design clinical trials. Your data may be used in multiple studies over many years."

**Section 4: Privacy Protections** (Address fears)

- "We'll remove your name and other identifying information. Data will be stored in secure, encrypted databases. Only approved researchers will access data, and they'll sign agreements not to try to identify you."

**Section 5: Risks** (Honest)

- "Risk of re-identification: Very low but not zero. Someone with enough information might figure out data is yours. We take steps to prevent this, but no system is perfect."
- "Emotional risk: Seeing your data may be upsetting (e.g., decline in lung function). You can choose not to view your own data."
- "Incidental findings: If we discover something unexpected (e.g., gene for Alzheimer's), we'll discuss with you whether you want to know."

**Section 6: Benefits** (Realistic)

- "You may not benefit directly, but your data will help future AATD patients. You'll get free access to your data and can learn from research findings."

**Section 7: Voluntary & Withdrawal** (Emphasize choice)

- "Participation is completely voluntary. You can withdraw anytime by emailing registry@markeglyfoundation.org. We'll stop collecting new data, but data already shared with researchers may be used (can't un-share, but no new sharing)."

**Section 8: Questions & Contact** (Accessible)

- "Questions? Contact Privacy Officer: privacy@markeglyfoundation.org, (XXX) XXX-XXXX. Independent ethics review: [IRB contact info]."

---

### Tiered Consent (Patients Choose Level)

**Level 1: Basic Consent** (Most participants)

- âœ… Share de-identified medical records, test results (FEV1, AAT level, imaging reports)
- âœ… Complete annual survey (health update, medications, hospitalizations)
- âŒ No biospecimens (no blood draws, sputum)
- âŒ No genetic data sharing beyond SERPINA1 genotype (whole genome stays private)
- **Burden**: Low (annual survey 15 minutes, no clinic visits)

**Level 2: Enhanced Consent** (Engaged participants)

- âœ… Everything in Level 1
- âœ… Share whole genome data (if availableâ€”23andMe, clinical sequencing)
- âœ… Quarterly surveys (PROs, symptom diariesâ€”more granular data)
- âœ… Wearable data (FitBit, Apple Watchâ€”if patient uses)
- âŒ No biospecimens (still no blood draws)
- **Burden**: Moderate (quarterly surveys 30 minutes, link wearablesâ€”1 hour setup)

**Level 3: Research Partner Consent** (Super-participants, ~10-20% of registry)

- âœ… Everything in Level 1 + 2
- âœ… Donate biospecimens (one-time blood draw 30 mL, optional sputum, tissue if biopsy done clinically)
- âœ… Participate in ancillary studies (researcher contactsâ€”"We're studying lung microbiome, would you provide sputum sample?")
- âœ… Re-contact for clinical trials (if eligibleâ€”Foundation asks "Would you like to hear about gene therapy trial?")
- **Burden**: High (clinic visit for blood draw, additional surveys/studiesâ€”10-20 hours/year, committed participants)

**Why Tiered?**

- Inclusivity (low-burden optionâ€”more patients participate, larger registry)
- Depth (high-burden optionâ€”rich data for advanced research, subset willing to do more)
- Respect autonomy (patients choose levelâ€”empower, not coerce)

---

## Data Collection Methods

### Method 1: Patient Portal (Foundation Website)

**Patient Dashboard** (MarkEglyFoundation.org/MyDataâ€”login with email/password):

**Features**:

- **Enroll** (consent form onlineâ€”DocuSign, eSign, HIPAA-compliant, timestamp)
- **Upload records** (PDF of medical records, lab resultsâ€”drag/drop, Foundation staff extract data manually or OCR)
- **Complete surveys** (quarterly health updateâ€”15 questions, 10 minutes, web-based)
- **View your data** (optionalâ€”patients see their own de-identified data, graphs [FEV1 over time], compare to registry average [anonymized])
- **Manage consent** (change level, withdraw, update contact infoâ€”patient control)

**Advantages**: Convenient (home, anytime), patient-driven (Foundation doesn't need to chase), scalable (1,000 or 10,000 patients, same portal)

**Challenges**: Tech literacy (older patients struggleâ€”Foundation offers phone support, paper forms if needed), Data quality (patient-entered = errorsâ€”Foundation validates, follows up on anomalies)

---

### Method 2: EHR Integration (Automated Data Pull)

**Partnership with Health Systems**:

- Foundation partners with Cleveland Clinic, National Jewish, UF, MUSC (Centers of Excellenceâ€”many AATD patients)
- Hospitals grant Foundation data access (via FHIR APIâ€”Fast Healthcare Interoperability Resources, modern EHR standard)
- Automated nightly pulls (Foundation queries EHRâ€”"Send updated FEV1, labs, meds for Patient P000042," data flows automatically)

**Advantages**: Complete data (no patient burdenâ€”data collected during clinical care, not extra), Real-time (new FEV1 test done todayâ€”in registry tomorrow), Accurate (no manual entry errorsâ€”direct from hospital system)

**Challenges**: Privacy complexity (hospitals cautiousâ€”HIPAA, legal agreements slow [6-12 months negotiation]), Technical hurdles (EHR integration expensiveâ€”$50K-$100K per hospital, requires IT resources), Limited to partnered hospitals (patients at non-partner hospitals must self-report)

**Foundation Priority**: Start manual (patient portal Year 1-2), add EHR integration Year 3+ (as Foundation budget, IT capacity grows)

---

### Method 3: Biospecimen Collection (Research Partner Participants)

**Blood Draw Options**:

- **Option A: At clinic visit** (patient sees pulmonologistâ€”Foundation arranges blood draw same day, no extra trip)
- **Option B: Mobile phlebotomy** (Foundation contracts Examine.com, Quest Patient Service Centerâ€”phlebotomist comes to patient's home)
- **Option C: Mail-in kit** (patient orders kitâ€”includes lancet [finger prick], blood spot card, mail backâ€”dried blood spots stable at room temp, genomic DNA extractable)

**Storage**:

- Biobank (Cleveland Clinic, Mayo, or commercial [RUCDR Infinite Biologics]â€”Foundation ships samples, stored -80Â°C freezer)
- Aliquots (1 sample â†’ 10 tubesâ€”researchers request 1 tube, 9 remain for future, maximize utility)
- Chain of custody (trackedâ€”every sample labeled Patient ID + Collection Date + Aliquot #, barcode scanned at every step)

**Research Access**:

- Researcher submits request ("I need 100 Pi\*ZZ plasma samples for proteomic study")
- Scientific Advisory Board approves
- Biobank ships samples (dry ice, overnightâ€”maintain cold chain, preserve integrity)
- Researcher returns unused aliquots (if applicableâ€”not consumed in assay)

**Cost**: $100-$200/patient (collection, processing, storageâ€”Foundation funds, patient free)

---

## Research Access Governance

### Who Can Access Data?

**Eligible Researchers**:

- âœ… Academic scientists (universities, medical centersâ€”PI with track record, IRB approval)
- âœ… Biotech/pharma (if partnering with Foundationâ€”e.g., Beam Therapeutics gene therapy research, Foundation co-owns results)
- âœ… Government researchers (NIH, FDAâ€”public interest, non-commercial)
- âŒ Commercial entities alone (no pharma accessing data without Foundation partnershipâ€”avoid exploitation, patients didn't consent to corporate profit without benefit)

---

### Data Request Process (Step-by-Step)

**Step 1: Application** (Online form):

- Researcher submits proposal (2-3 pagesâ€”research question, methods, variables needed, timeline, publication plan)
- CV/biosketch (demonstrate expertiseâ€”published in field, qualified to do proposed work)
- IRB approval (if study involves human subjectsâ€”local IRB reviewed, approved, protects patients)

**Step 2: Scientific Review** (Foundation's Scientific Advisory Board):

- Monthly meeting (SAB reviews all applicationsâ€”scientific rigor, feasibility, importance)
- Scoring (1-5 scaleâ€”5 = excellent, must fund, 1 = poor, reject)
- Decision (approve, request revisions, rejectâ€”feedback provided, encourage resubmission if close)

**Step 3: Data Use Agreement** (Legal Contract):

- Researcher signs (agree to Foundation's termsâ€”no re-identification attempts, no data sharing without permission, cite Foundation in publications, return unused biospecimens)
- Institution signs (university cosignsâ€”institutional responsibility, liability)
- Foundation signs (all parties boundâ€”enforceable)

**Step 4: Data Access** (Secure Transfer):

- Foundation prepares dataset (de-identified, specific variables requestedâ€”not full database, minimal necessary)
- Transfer via secure portal (encrypted uploadâ€”researcher downloads, or mailed hard drive [encrypted])
- Access for defined period (1-2 yearsâ€”enough to complete study, then data deleted [unless renewal granted])

**Step 5: Publication Review** (Not Censorship, Factual Accuracy):

- Researcher submits manuscript draft (Foundation reviewsâ€”ensure data interpreted correctly, Foundation acknowledged, no re-identification risk in publication)
- Foundation suggests edits (if errors, misinterpretationsâ€”no veto over negative findings, just factual accuracy)
- Researcher submits to journal (Foundation citationâ€”"Data provided by Mark Egly Foundation AATD Registry")

**Step 6: Data Return/Destruction** (End of Project):

- Researcher deletes data (certifies deletionâ€”email confirmation, legally binding)
- Unused biospecimens returned (if applicableâ€”ship back to biobank, can't keep)
- Final report to Foundation (summaryâ€”what was learned, publications resulting, impact)

---

### Publication Policy

**Foundation Requirements**:

- âœ… **Acknowledge Foundation** (in manuscriptâ€”"Supported by Mark Egly Foundation registry" or "Data from Mark Egly Foundation," proper credit)
- âœ… **Cite registry** (if registry has publication describing itâ€”cite that paper, helps Foundation's academic credibility)
- âœ… **Share preprints** (send Foundation draft before journal submissionâ€”review for accuracy, not approval, transparency)
- âŒ **No publication veto** (Foundation can't block publication because results unfavorableâ€”academic freedom, credibility essential)

**Co-Authorship**:

- Foundation staff co-author if substantial contribution (designed study, analyzed data, wrote manuscriptâ€”earned authorship)
- Not automatic (researcher used data â‰  Foundation co-authorâ€”avoid gift authorship, dilutes meaning)

---

## Patient Incentives

### Why Patients Participate (Intrinsic + Extrinsic Motivation)

**Intrinsic** (Most Powerful):

- âœ… **Altruism** ("Help future patientsâ€”cure for my kids, grandkids")
- âœ… **Sense of purpose** ("AATD took so much from me, donating data gives back")
- âœ… **Community** ("I'm part of something biggerâ€”10,000 patients united")

**Extrinsic** (Helpful, Not Sufficient Alone):

- âœ… **Access to own data** (see your FEV1 trends, compare to othersâ€”self-knowledge valuable)
- âœ… **Research results** (Foundation emails summariesâ€”"Your data helped discover genetic modifier," recognition)
- âœ… **Tax deduction** (genetic data = property, donating = charitable contribution?â€”see Tax Deduction Strategy doc, experimental but possible)
- âœ… **Clinical trial priority** (registry participants learn about trials firstâ€”early access to experimental treatments)
- âœ… **Free genetic testing upgrade** (registry participants get whole genome sequencingâ€”$1,000 value, Foundation-funded, research + personal benefit)

---

### Tax Deduction for Data Donation (Innovative Incentive)

**Legal Theory**:

- Genetic data = intellectual property (similar to art, manuscriptâ€”tangible property, market value)
- Donating IP to charity = charitable deduction (IRS allows deduction for donated propertyâ€”fair market value)
- Value = cost to generate + research utility (whole genome sequencing costs $1,000, has research valueâ€”appraisal $1,000-$5,000?)

**Implementation**:

- Foundation works with tax attorneys (2-3 years to get IRS rulingâ€”Private Letter Ruling, or test in court)
- If approvedâ€”patients donate data, receive Form 8283 (noncash charitable contributionâ€”report on taxes, deduct $1K-$5K)
- **Incentive**: 1,000 patients donate data + deduct $3,000 average (save $750 taxes if 25% tax bracketâ€”worth it for patients, Foundation gets data, win-win)

**Risk**: IRS may challenge (novel approachâ€”precedent unclear, Foundation needs legal budget $100K-$200K to defend if challenged)

**See Full Analysis**: Tax Deduction Strategy for DNA Donation document (next in master plan)

---

## Technical Infrastructure

### Database Architecture

**Data Warehouse** (Centralized, Structured):

- **Platform**: REDCap (Research Electronic Data Captureâ€”gold standard for clinical research databases, HIPAA-compliant, used by thousands of universities)
- **Alternative**: Custom build on AWS/Azure (more flexible, expensiveâ€”$500K+ development, Foundation uses REDCap Year 1-5, consider custom Year 5+ if needs outgrow)

**Data Model** (Relational Database):

- **Tables**:
  - `Patients` (Patient_ID, Year_Of_Birth, Sex, State, Genotypeâ€”one row per patient)
  - `Lung_Function` (Patient_ID, Test_Date_Year, FEV1, FVC, DLCOâ€”multiple rows per patient, longitudinal)
  - `Medications` (Patient_ID, Start_Year, Drug_Name, Dose, Frequency)
  - `Surveys` (Patient_ID, Survey_Date, Question_1, Question_2, â€¦â€”PROs)
  - `Biospecimens` (Patient_ID, Collection_Date, Sample_Type, Biobank_ID, Location)
- **Relationships**: Patient_ID links tables (join queriesâ€”"Show me all FEV1 tests for Patient P000042")

**Data Dictionary** (Define Every Variable):

- FEV1 definition (Forced Expiratory Volume in 1 second, measured in liters, pulmonary function test, indicates lung obstruction)
- Units (L, mL, % predictedâ€”standardize, no mixing units)
- Valid range (FEV1 = 0.5 to 6.0 L in adultsâ€”values outside = data errors, flag for review)
- Missing data codes (999 = unknown, 888 = not applicable, 777 = refused to answerâ€”distinguish types of missingness)

---

### Security Infrastructure

**Network Security**:

- **Firewall** (block unauthorized accessâ€”only specific IPs can access database, e.g., Foundation office, approved researchers' institutions)
- **VPN** (Foundation staff access remotelyâ€”encrypted tunnel, no open internet access)
- **Intrusion detection** (monitor for attacksâ€”log all login attempts, flag suspicious [100 failed logins in 1 minute = attack])

**Database Security**:

- **Encryption at rest** (data on hard drives encryptedâ€”AES-256, if server stolen, data unreadable without key)
- **Encryption in transit** (data moving between servers, users encryptedâ€”HTTPS, TLS, prevent eavesdropping)
- **Role-based access control** (users assigned rolesâ€”"Registry Coordinator" can add patients, "Researcher" can query de-identified data, "Admin" can access identifiers, least privilege principle)
- **Audit logs** (every action loggedâ€”who accessed what data when, tamper-proof log, detect breaches)

**Backup & Disaster Recovery**:

- **Daily backups** (automatedâ€”3am daily, full database backup)
- **Off-site storage** (backups sent to AWS S3 Glacierâ€”geographically separate, if office burns down, data safe)
- **Test restores** (annuallyâ€”ensure backups work, many organizations don't test, discover corrupt backups too late)

---

### Cost

**Year 1 Setup**: $100K-$150K

- REDCap license: $5K-$10K/year (Vanderbilt Universityâ€”hosted, supported)
- Database design: $30K (consultantâ€”design schema, data dictionary, forms, 3 months work)
- Security audit: $20K (third-partyâ€”penetration test, HIPAA compliance review, certification)
- Legal review: $20K (privacy attorneyâ€”review consent forms, DUAs, policies)
- Biobank setup: $30K (negotiate with Cleveland Clinic Biobankâ€”freezer space, sample tracking system, 1 year)

**Ongoing**: $50K-$80K/year

- REDCap hosting: $10K/year
- Cloud storage: $5K/year (AWSâ€”database backups, de-identified datasets for researchers)
- Staff: $50K-$60K/year (0.5 FTE Database Managerâ€”answer researcher questions, prepare datasets, maintain system)
- Biobank storage: $10K-$20K/year (per-sample feesâ€”$20-$50/sample/year, 500 samples = $10K-$25K)

---

## Legal & Ethical Considerations

### IRB Oversight

**Foundation's IRB** (Institutional Review Board):

- External IRB (Foundation contracts with commercial IRB [WCG IRB, Advarra]â€”independent ethics review, avoid conflict of interest)
- Annual review (IRB reviews registryâ€”consent process, data security, any adverse events [breaches, patient complaints], approve continuation)
- Modifications (if Foundation changes consent form, adds new data typeâ€”IRB must approve before implementing)

**Cost**: $15K-$25K/year (IRB feesâ€”initial review $5K, annual renewal $3K, modifications $2K each, worth it for ethical oversight, legal protection)

---

### GINA Protections (Genetic Information Nondiscrimination Act)

**What GINA Covers**:

- âœ… **Health insurance** (insurers can't deny coverage, raise premiums based on genetic dataâ€”GINA 2008 federal law)
- âœ… **Employment** (employers can't refuse to hire, fire, discriminate based on genetics)

**What GINA Doesn't Cover**:

- âŒ **Life insurance** (companies can request genetic testing, deny coverage based on resultsâ€”legal)
- âŒ **Disability insurance** (sameâ€”can discriminate based on genetics)
- âŒ **Long-term care insurance** (same)

**Foundation's Disclosure**:

- Consent form explains GINA (patients know protectionsâ€”and gaps)
- Recommend caution ("If considering life insurance, purchase before genetic testing or data donationâ€”once in database, technically accessible to life insurers via court order [rare but possible]")

---

### International Considerations (GDPR if Expanding)

**If Foundation Expands to Europe** (Year 5+):

- **GDPR compliance** (General Data Protection Regulationâ€”EU privacy law, stricter than HIPAA)
- **Key differences**:
  - Right to erasure (patients can demand data deletedâ€”Foundation must comply, harder if data already shared with researchers)
  - Data minimization (collect only necessary dataâ€”can't hoard "just in case")
  - DPO required (Data Protection Officerâ€”Foundation must hire if processing EU data)
- **Cost**: $50K-$100K additional (legal, technical changes to complyâ€”worth it if reaching 50K European AATD patients)

---

## Implementation Roadmap

### Year 1: Foundation & Pilot (500 Participants)

**Q1-Q2: Infrastructure Setup**

- Contract with REDCap (Vanderbiltâ€”host database)
- Design database (data dictionary, formsâ€”Registry Coordinator + consultant)
- Develop consent forms (attorney reviewâ€”plain language, IRB approval)
- IRB submission (external IRBâ€”initial review, 4-6 weeks approval)

**Q3: Pilot Launch**

- Recruit 50 pilot participants (Foundation support groupsâ€”"We're launching registry, will you join?," feedback)
- Test enrollment process (find bugsâ€”consent confusing? portal crashes?â€”fix before full launch)
- Collect first data (annual surveys, medical records uploadâ€”validate data quality)

**Q4: Full Launch**

- Recruit broadly (website, social media, eventsâ€”"Join registry, help research")
- Goal: 500 participants by end Year 1 (5% of diagnosed US patientsâ€”strong start)
- First researcher data request (by Q4â€”Foundation processes, tests data release workflow)

**Cost Year 1**: $200K (setup $150K + ongoing $50K half-year)

---

### Year 2: Growth & Engagement (1,500 Total Participants)

**Goals**:

- Add 1,000 participants (double Year 1â€”momentum building, word-of-mouth)
- Launch biobank (pilotâ€”50 participants donate blood, test logistics)
- First research publication (Foundation-led paperâ€”"The Mark Egly Foundation AATD Registry: Design, Methods, Baseline Characteristics," describe registry, recruit researchers)

**Enhancements**:

- Mobile app (iOS/Androidâ€”patients complete surveys on phone, more convenient, better compliance)
- Data dashboard (patients view own dataâ€”FEV1 graphs, anonymized comparisons, engagement)

**Cost Year 2**: $150K (growth + enhancements)

---

### Year 3: Scale & Partnerships (3,000 Total Participants)

**Goals**:

- Add 1,500 participants (continued growthâ€”30% of diagnosed patients enrolled, major milestone)
- EHR integration pilot (Cleveland Clinicâ€”automated data pull, test before broader rollout)
- 10 researcher projects (Foundation data used in 10 studiesâ€”demonstrate utility, publications)

**Partnerships**:

- Partner with 23andMe (23andMe identifies AATD patientsâ€”invites to join Foundation registry, 1,000+ additional participants)
- Partner with pharma (Grifols, CSLâ€”patients on augmentation invited to join registry, industry collaboration)

**Cost Year 3**: $200K (EHR integration $100K, operations $100K)

---

### Year 4-5: Maturity (5,000 Total Participants, Research Acceleration)

**Goals**:

- Add 1,000 participants/year (steady stateâ€”new diagnoses, ongoing recruitment)
- 50 research projects (Foundation data = go-to resource for AATD researchers worldwide)
- International expansion (pilotâ€”100 European patients, test GDPR compliance)

**Impact**:

- Natural history publication (10-year FEV1 decline in 3,000 Pi\*ZZ patientsâ€”definitive study, cited in every future AATD trial)
- Gene therapy trial (Foundation registry = recruitment platformâ€”AGTC trial enrolls 100 patients in 6 months [instead of 3 years], accelerates approval)

**Cost Year 4-5**: $250K/year (mature operations, larger scale)

---

### Year 10 Vision: World's Largest AATD Database

**10,000 Participants** (10% of all US AATD patients, 50% of diagnosed):

- 20 years longitudinal data (patients enrolled Year 1 still participating Year 10â€”track entire disease course)
- 100+ publications (Foundation-supported research transforms AATD science)
- 2,000 biospecimens (biobank enables omics researchâ€”proteomics, metabolomics, next-gen discoveries)

**Foundation = Scientific Hub**:

- Every AATD clinical trial recruits from registry (gene therapy, new drugs, diagnosticsâ€”all use Foundation)
- FDA cites Foundation data (regulatory decisionsâ€”drug approvals, label changes, registry = real-world evidence gold standard)
- Patients worldwide benefit (US registry informs European, Asian careâ€”Foundation's data = global public good)

---

## Summary

**Anonymous Data Donation Program = Foundation's Research Accelerator**:

- âœ… **10,000-Patient Registry by Year 10** (10x larger than any existingâ€”world's premier AATD research resource)
- âœ… **Privacy-First** (HIPAA-compliant, de-identified, secureâ€”patients trust Foundation with sensitive data)
- âœ… **Patient-Centric** (tiered consent, access to own data, altruism + incentivesâ€”empower patients)
- âœ… **Research Impact** (natural history, treatment effectiveness, clinical trials accelerationâ€”cure faster)

**Investment**: $200K Year 1, $150K-$250K/year ongoing (2-3% of Foundation budgetâ€”highest ROI program)

**ROI**:

- Scientific publications: 100+ over 10 years (Foundation-supported research)
- Clinical trials accelerated: 2-5 years faster enrollment (gene therapy approved 2032 vs. 2035)
- Patients helped: Millions globally (Foundation's data informs care worldwide)

**"Your data today saves lives tomorrow."**

---

**Registry Enrollment**

**Mark Egly Foundation AATD Registry**
ðŸ“§ Email: registry@markeglyfoundation.org
ðŸ“ž Phone: (XXX) XXX-XXXX
ðŸŒ Website: MarkEglyFoundation.org/Registry

---

**Approved by**: Board of Directors, Scientific Advisory Board, IRB
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"Data for discovery. Privacy with purpose."_

**â€” Mark Egly Foundation**
